Hard to Treat Diseases Inc. (HTDS) Stem Cell Developments

Jan 19, 2010, 11:39 ET from Hard to Treat Diseases

FRANKFURT, Jan. 19 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) and its operating subsidiary Slavica BioChem want to point the shareholders back to the press release from Oct 29, 2009, where the company announced news about a possible merger with a EU based, stem-cell research company.

HTDS postponed these merger negotiations due to certain HTDS' "followers" certain intrusive intervention and a massive short position on HTDS security. As previously announced, the company has begun a project to build its own stem cell lab. Details will be posted on the company web site under the section "Company News" as the company no longer subscribes to Pink Sheets filing service. HTDS' sale of the MindUp program to Hiru Corporation in Q4 2009 has now created an opportunity for the company to create its own stem cell facility.

HTDS also found many members of the public sharing dismissive attitudes towards these merger talks and to break this unconstructive position. The constant bashings on line calling the company "scam" and intentional disruptive innuendoes took their toll on the new and novice shareholders and small businesses that were entertaining HTDS merger proposals. The company through its IR's legal complaint as a beneficiary took certain legal actions and joined in a law suit. These documents will be displayed in the Company News section. The company makes this open invitation to any shareholder and follower to visit the company facilities in China and Serbia to satisfy themselves with the company operations. The company believes at least 2 posters, Firelane and Marine1 (who also use different pseudonyms on other chat boards), are in fact employees or agents of InvestorsHub, a defendant in a multi million dollar slander lawsuit which the company is a beneficial recipient. This InvestorsHub and its principals has been cited by authorities in the USA for many irregularities. The company reminds its followers not to seek investment advice from Internet chat boards.

For this purpose and the stem cell division development HTDS launched a section of its corporate website (http://www.htdsmedical.com/stem/index.html) with a link from the "Company News" section as well where the shareholders can review images of the previously targeted facility, and the technology.

A source close to the company said, "These stock bashers are disruptive to a legitimate business, many have been identified and legal action is being taken against many and those that provide them with a safe forum to spread false rumours and dark propaganda. Be that as it may, their actions have actually helped the company in this case and created a long term opportunity for HTDS. For example, when we looked at the merger candidate we learned that the most economical way to go about this project is to simply lease space and 'try before we make a major investment or buy the business which may or may not work'". We also learned that the targeted merger candidate did exactly this several years ago. They simply built the business and with the cash flows the business produced from a leased facility they spring boarded to the point where they now have their own stem cell lab. HTDS management believes it can do the same, and better.

In other updates, the company believes (as no one will furnish it with another explanation) that the "skull and bones" rank from an unqualified self regulator stems from the HTDS stubborn naked short position and settlement actions. As with the planned distribution of the MindUp division to its shareholders, the company is looking at other ways to shake the naked shorts and, more importantly, return values to its shareholders. A friendly reverse takeover is one option being explored by the company with an unrelated entity engaged in a medical rejuvenative reconstruction, an unrelated issuer in a medical industry HTDS and a medical supply development company thus creating a 4-way medical conglomerate.

HTDS will shortly start a division to focus on research and storage of the umbilical cord stem cells, the only ethical source of stem cells in the human body. Umbilical stem cells are more flexible in medical applications and possess 30% higher flexibility to match the patient than the bone marrow stem cells do. The company will also serve its customers as an Umbilical Cord Blood Bank. The umbilical cord blood (UCB) is stored for treatment of leukemia, anaemia and other haematological conditions in the donor's family only.

To be included in HTDS' email database for press releases and industry updates, please subscribe at or opt in with your email address at this link: http://www.minamargroup.com/updates/.

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

SOURCE Hard to Treat Diseases